Condition: Major Depressive Disorder · Sponsor: Neurocrine Biosciences
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
This description comes directly from the study's public registry record.
Neurocrine Medical Information Call Center · 1-877-641-3461 · medinfo@neurocrine.com
Always discuss trial participation with your own doctor first.
| Neurocrine Clinical Site | Huntsville, Alabama, United States | Recruiting |
| Neurocrine Clinical Site | Glendale, California, United States | Recruiting |
| Neurocrine Clinical Site | Irvine, California, United States | Recruiting |
| Neurocrine Clinical Site | Miami, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Tampa, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Atlanta, Georgia, United States | Recruiting |
| Neurocrine Clinical Site | Boston, Massachusetts, United States | Recruiting |
| Neurocrine Clinical Site | Saint Charles, Missouri, United States | Recruiting |
| Neurocrine Clinical Site | The Bronx, New York, United States | Recruiting |
| Neurocrine Clinical Site | Mason, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06911112